Full history for every metric is available with a Kvantra account
Opiant Pharmaceuticals, Inc. (OPNT)
Key financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | ||
|---|---|---|---|---|---|---|---|
| Total revenue | $m | 10 | 18 | 14 | 38 | 27 | 41 |
| Operating profit | $m | 5 | |||||
| Net profit | $m | -8 | 7 | -21 | 12 | -2 | 3 |
| EPS reported | $ | 0.51 | |||||
| Operating cashflow per share | $ | 0.43 | |||||
| Capex per share | $ | 0.00 | |||||
| FCF per share | $ | 0.43 | |||||
| Free cash flow | $m | 2 | |||||
| Net debt | $m | -36 | |||||
| Book value equity | $m | 47 | |||||
| Book value per share | $ | 7.91 | |||||
| Number of shares | m | 5.92 | |||||
| DPS (TTM paid) | $ | 0.00 |
Financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | ||
|---|---|---|---|---|---|---|---|
| Value | |||||||
| P/E TTM | x | 65.94 | |||||
| P/B LTM | x | 3.20 | |||||
| P/S LTM | x | 3.68 | |||||
| P/FCF LTM | x | 77.79 | |||||
| EV/EBITDA LTM | x | 22.14 | |||||
| EV/Sales LTM | x | 3.17 | |||||
| Earnings Yield LTM | % | 1.52% | |||||
| FCF Yield | % | 1.29% | |||||
| Quality | |||||||
| ROE | % | 6.42% | |||||
| ROIC | % | 8.00% | |||||
| Operating margin | % | 12.66% | |||||
| Gross margin | % | 77.74% | |||||
| FCF/Sales | % | 4.73% | |||||
| Growth and momentum | |||||||
| EPS Growth YoY | % | - | |||||
| Sales Growth YoY | % | +48.62% | |||||
| Net Income Growth YoY | % | - | |||||
| FCF Growth | % | - | |||||
| Operating Profit Growth | % | - | |||||
| Dividend and capital structure | |||||||
| Dividend Yield | % | 0.00% | |||||
| Dividend Growth | % | 0.00% | |||||
| Payout Ratio | % | 0.00% | |||||
| FCF/Debt | x | 0.11 | |||||
| Net Debt/EBITDA | x | -3.56 | |||||
| EBIT/Net interest | x | 2.42 | |||||
| Net debt/market cap | % | -23.88% | |||||
| Net debt/Equity | x | -0.76 | |||||
| Gross debt/equity | x | 0.36 | |||||
Company overview
Opiant Pharmaceuticals, Inc. functions as a specialized pharmaceutical enterprise, primarily focused on inventing remedies for both various addictions and drug overdoses. A key product in their current portfolio is NARCAN nasal spray, which provides a critical solution for counteracting opioid overdoses. Their development pipeline is robust, featuring several promising drug candidates designed to address further opioid overdose reversal needs, alcohol use disorders, acute cannabinoid overdose, and opioid use disorders. The company, which established itself in 2005, was initially named Lightlake Therapeutics Inc. before rebranding as Opiant Pharmaceuticals, Inc. in January 2016. Its corporate headquarters are located in Santa Monica, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Opiant Pharmaceuticals, Inc. (OPNT)
Opiant Pharmaceuticals, Inc. functions as a specialized pharmaceutical enterprise, primarily focused on inventing remedies for both various addictions and drug overdoses. A key product in their current portfolio is NARCAN nasal spray, which provides a critical solution for counteracting opioid overdoses. Their development pipeline is robust, featuring several promising drug candidates designed to address further opioid overdose reversal needs, alcohol use disorders, acute cannabinoid overdose, and opioid use disorders. The company, which established itself in 2005, was initially named Lightlake Therapeutics Inc. before rebranding as Opiant Pharmaceuticals, Inc. in January 2016. Its corporate headquarters are located in Santa Monica, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free